Sugi Predict
/ Targets
/ POLR1A
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to POLR1A by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers |
PHASE1/PHASE2 | COMPLETED |
| Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer |
PHASE2 | COMPLETED |
| Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis |
PHASE2 | ACTIVE_NOT_RECRUITING |
| PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS |
PHASE2 | COMPLETED |
| Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
PHASE2 | ACTIVE_NOT_RECRUITING |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas |
PHASE1 | COMPLETED |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors |
PHASE1 | COMPLETED |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors |
PHASE1 | ACTIVE_NOT_RECRUITING |
| AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers |
PHASE1 | COMPLETED |
| A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors |
PHASE1 | COMPLETED |
| A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors |
PHASE1 | COMPLETED |
| ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer |
PHASE1 | COMPLETED |
| ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors |
PHASE1 | WITHDRAWN |
| PET Imaging of PARP Activity in Cancer |
EARLY_PHASE1 | UNKNOWN |
| Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC |
EARLY_PHASE1 | RECRUITING |
| Chromosomal Translocations in Chandigarh Police |
nan | COMPLETED |
| A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients |
nan | COMPLETED |
| DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease |
nan | COMPLETED |
| Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics |
nan | UNKNOWN |
| Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome) |
nan | COMPLETED |
| Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases |
nan | UNKNOWN |
| Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer |
nan | UNKNOWN |
| Study of the Effect of Innate on the Inflammatory Response to Endotoxin |
nan | RECRUITING |
| S8814A Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil |
nan | COMPLETED |
| Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients |
nan | ACTIVE_NOT_RECRUITING |
| Prognostic Biomarkers in Patients With Urothelial Carcinoma |
nan | COMPLETED |
| Impact of Bariatric and Metabolic Surgery on the Reduction of Premature Aging. |
nan | COMPLETED |
| Cohort of Tumors With POLE/D1 Mutation |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a POLR1A binder may also engage these)